- Report
- September 2024
- 110 Pages
Global
From €5265EUR$5,950USD£4,552GBP
- Report
- March 2025
- 200 Pages
Global
From €2203EUR$2,490USD£1,905GBP
- Report
- August 2025
- 192 Pages
Global
From €3137EUR$3,545USD£2,712GBP
€3485EUR$3,939USD£3,014GBP
- Report
- August 2025
- 190 Pages
Global
From €3137EUR$3,545USD£2,712GBP
€3485EUR$3,939USD£3,014GBP
- Report
- August 2025
- 181 Pages
Global
From €3137EUR$3,545USD£2,712GBP
€3485EUR$3,939USD£3,014GBP
- Report
- August 2025
- 150 Pages
Global
From €3407EUR$3,850USD£2,946GBP
- Report
- June 2025
- 150 Pages
Global
From €3407EUR$3,850USD£2,946GBP
€4291EUR$4,850USD£3,711GBP
- Report
- April 2025
- 175 Pages
Global
From €3973EUR$4,490USD£3,435GBP
- Report
- April 2025
- 200 Pages
Global
From €3973EUR$4,490USD£3,435GBP
- Report
- April 2025
- 200 Pages
Global
From €3973EUR$4,490USD£3,435GBP
- Report
- April 2025
- 200 Pages
Global
From €3973EUR$4,490USD£3,435GBP
- Report
- July 2025
- 150 Pages
Global
From €3407EUR$3,850USD£2,946GBP
€4291EUR$4,850USD£3,711GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2655EUR$3,000USD£2,295GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1327EUR$1,500USD£1,148GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €1106EUR$1,250USD£956GBP
- Report
- September 2025
- 197 Pages
Global
From €5176EUR$5,850USD£4,476GBP
- Report
- September 2025
- 179 Pages
Global
From €5176EUR$5,850USD£4,476GBP
- Report
- September 2025
- 177 Pages
Global
From €5176EUR$5,850USD£4,476GBP
- Report
- September 2025
- 288 Pages
Global
From €5176EUR$5,850USD£4,476GBP
- Report
- September 2025
- 340 Pages
Global
From €5176EUR$5,850USD£4,476GBP

The Sodium Dependent Glucose Co Transporter 2 (SGLT2) market is a subset of the Endocrine and Metabolic Disorders Drugs market. SGLT2 inhibitors are a class of drugs used to treat type 2 diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin effectively. These drugs work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to reduce blood glucose levels and improve glycemic control.
The SGLT2 market is highly competitive, with several major pharmaceutical companies offering products. These include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. Each company offers a range of products, including both branded and generic versions. Show Less Read more